Trial Results Anticipated First Half 2019
Jena, Germany, November 08, 2018 – InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that patient enrollment has been completed in the phase IIb study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS). HS is a painful and debilitating chronic inflammatory skin disease with limited treatment options.
The randomized, double-blind, placebo-controlled, multicenter study is being conducted at 38 sites in both North America and Europe. Following a placebo-controlled, double-blind period of 16 weeks investigating four different IFX-1 dosing arms plus one placebo arm, there is a 28-week open-label extension phase to assess long-term efficacy and safety. The primary endpoint is dose response signal, assessed by the Hidradenitis Suppurativa Clinical Response (HiSCR) score, at week 16. Additional objectives include the evaluation of safety and tolerability of IFX-1, as well as an assessment of additional efficacy and patient-reported outcome parameters. Topline results from the trial are expected in the first half of 2019.
Othmar Zenker, M.D., Chief Medical Officer of InflaRx, said: “We are very pleased to have completed enrollment in this Phase IIb trial within our stated timeframe. Following the promising results we observed in our earlier trial with IFX-1 in Hidradenitis Suppurativa, our goal with this phase IIb study is to determine the optimal dose regimen, as well as assess both long‑term efficacy and safety of IFX-1 in patients with this disease.”
Prof. Dr. med. Evangelos J. Giamarellos-Bourboulis, of the ATTIKON University Hospital in Athens, Greece, the principal investigator of this trial, said: “Hidradenitis Suppurativa is a debilitating, painful and frequently life-long disease. For patients with moderate to severe HS, treatment options are limited, and there is an urgent need to find more effective therapies. The C5a blockade with IFX-1 offers an entirely new mode of action to tackle this disease, and I look forward to seeing the results from this study.”
IFX-1 is a first-in-class monoclonal anti-complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development and has, to date, successfully completed three clinical phase II studies. Until today, more than 150 people have been treated with IFX-1 within completed clinical trials, which was well tolerated. IFX-1 is currently being developed for various inflammatory indications, including Hidradenitis Suppurativa and ANCA-associated vasculitis.
About InflaRx N.V.:
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan.
Head of Corporate Development and Strategy
+1 917 837 1709
MC Services AG
Katja Arnold, Laurie Doyle, Andreas Jungfer
+49 89 210 2280
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.